TABLE 4.
Summaries of available therapeutics from various recombinant LAB.
| Strains | Therapeutic products | Health-related condition | References |
|---|---|---|---|
| Lactococcus lactis | Interleukin-10, proinsulin | Diabetes mellitus (Type I) | Steidler et al. (2000) |
| Lactococcus lactis NZ9000 | Interleukin-12 | Asthma | Bermúdez-Humarán et al. (2003) |
| Lactococcus lactis NZ9000 | HSP65–6P277 | Diabetes mellitus (Type I) | Ma et al. (2014) |
| Lactococcus lactis NZ9000 | Kisspeptin | Colorectal cancer | Zhang et al. (2016) |
| Lactococcus lactis NZ9000, Lactobacillus casei | HPV-16-E7 | Human papillomavirus 16-induced cancers | (Bermúdez-Humarán et al., 2005)–– |
| Lactococcus lactis IL1403 | Interleukin-6 | Adjuvant | Li et al. (2015) |
| Lactococcus lactis CHW9 | Peanut allergen Ara2 | Hypersensitivity intolerance (Type I) | Glenting et al. (2007) |
| Lactococcus lactis NZ9800 | Birch allergen Betv1 | Hypersensitivity intolerance (Type I) | Daniel et al. (2006) |
| Lactococcus lactis MG1363 | Glycosylated tyrosinase-related protein-2 | Skin cancer | Kalyanasundram et al. (2015) |
| Lactobacillus plantarum NCL21 | Japanese cedar pollen allergen Cry j1 | Hypersensitivity intolerance (Type I) | Ohkouchi et al. (2012) |
| Lactobacillus pentosus SS6 | γ-Amino butyric acid | Anxiety, hypertension | Zhong et al. (2019) |
| Lactobacillus acidophilus PTCC1643 | Hyaluronic acid | Dermatitis, wound healing | Chahuki et al. (2019) |